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the model (relapse rates, drop-out rates, switching to
other antipsychotics, adverse effects and other transition
probabilities) were obtained from literature. The clinical
management pattern and cost of therapy in various
model states reflected treatment practice for Polish schizo-
phrenic patients. The model was directed by clinical
guidelines issued in 1997 and adjusted to current clinical
practice. The costs, calculated from the sum of the
charges applicable to each of the management situations
over time, were expressed in 2000 PPP USD values. Boot-
strapping technique was used to evaluate the 95% CI for
mean cost of therapy with both alternative drugs.
RESULTS: The model revealed 11% higher lower relapse
among risperidone patients as compared with haloperi-
dol patients. The mean cost of therapy with risperidone
equaled 11,412 USD. First line treatment with haloperi-
dol resulted in average cost of 11,154 USD. The differ-
ence between both therapies tested by bootstrapping
techniques was not statistically significant.
CONCLUSION: The therapy costs with risperidone and
haloperidol are comparable in Polish clinical and eco-
nomic settings. Higher clinical effectiveness of risperi-
done produces savings, thereby balancing drug cost.
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OBJECTIVE: To evaluate whether 6-, 9-, and 12-month
rates of persistency (long-term compliance) with initially
prescribed antipsychotic monotherapy translate into cost
savings.
METHODS: We identified 220 newly diagnosed psy-
chotic patients from approximately 180 managed care
organizations who were initiated on quetiapine mono-
therapy during an 18-month period. Patients were ran-
domly selected and matched by study date to populate
three comparator groups: a haloperidol group; a risperi-
done group, and patients initiated on any atypical agent
except quetiapine. Patients were tracked for at least one
year to identify whether they remained on monotherapy,
added to the therapy, switched, or discontinued it. Psy-
chiatric costs were aggregated by service type. Analyses
included tests of proportions for rates, Cox proportional
hazard models for time, and linear regressions for cost.
RESULTS: At six months, 62.73% of quetiapine patients
remained on monotherapy vs 33.51% of haloperidol pa-
tients (p  .01), 44.60% of risperidone patients (p 
.01), and 41.57% of the composite cohort (p  .01). At
nine months, 47.73% of quetiapine patients remained on
monotherapy vs 23.71% of haloperidol patients (p 
.01), 38.97% of risperidone patients (p  0.06), and
32.78% of the composite cohort (p  .01). At one year,
35.45% of quetiapine patients remained on monotherapy
vs 13.40% of haloperidol patients (p  .01), 31.46% of
risperidone patients (p  0.37), and 26.13% of the com-
posite cohort (p  0.01). All three comparisons were sta-
tistically different; median values were 220 days for que-
tiapine, 90 for haloperidol (p  .01), 159 for risperidone
(p  0.02), and 141 for the composite cohort (p  .01).
Annual costs were reduced by $4.39 per additional day
(p  .01) of persistency with the initially prescribed anti-
psychotic. Combining multivariate results shows cost
savings for quetiapine of $570.70/year per patient com-
pared with haloperidol, $250.23/year per patient com-
pared with risperidone, and $307.30 if quetiapine were
the atypical antipsychotic of first choice.
CONCLUSION: When quetiapine is the first-line thera-
peutic choice, more patients remain compliant, and cost
savings result.
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OBJECTIVE: The purpose of this article is to assess the
impact of alcohol abuse on employment in Switzerland.
We used the database from the Swiss Health Survey 1997
to determine the incidence of excessive alcohol consump-
tion on unemployment and productivity at work. To
date, it would appear that this data has never yet been
used in order to analyze such a link.
METHODS: Our approach to the impact of alcohol
abuse on unemployment is traditional and resorts to a
probit model of the probability of being unemployed ac-
cording to variables relating to health and socio-eco-
nomic status. On the other hand, we consider that alco-
hol consumption can have a different impact on income
depending on consumption thresholds. To determine
these thresholds, we adopted the approach by Tsay
(1989) that implies the convergence of the recursive Stu-
dent-t statistics of the estimated coefficient related to the
variable “ALCOHOL” if the model is linear. If this is not
the case, the model possesses two or more regimes (deter-
mined by ruptures of the recursive t).
RESULTS and CONCLUSION: Concerning unemploy-
ment, and for men and women alike, a very high con-
sumption of alcohol has a positive impact on the proba-
bility of becoming unemployed. Regarding the effect of
alcohol consumption on earnings, we find the same re-
sults as the majority of authors, but with a multiple re-
gimes model. Thus, for men, the daily consumption of at
most one glass of an alcoholic drink has a positive impact
on their income. Beyond this quantity the effects are null,
but two sub-regimes are detected with different specifica-
tions. For women, alcohol consumption has a positive ef-
fect on their salary below 2.5 alcohol units per day, and
has no effect beyond this.
